Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shanghai Genomics Inc.

Division of GNI Group Ltd.
www.shanghaigenomics.com

Latest From Shanghai Genomics Inc.

China’s HEC Plans Novel IPF Study To Make Splash In US

Tommy Lin, head of Business Development and Global Licensing for HEC Pharma, talks to Scrip’s Brian Yang on how the Chinese domestic drug company is looking to develop its anti-fibrosis drug in the US.

Commercial China

Roche’s Pirfenidone Bet Validates China Venture

China was probably not a major consideration in Roche’s $8 billion-plus bet on U.S. biotech InterMune and its mainstay product pirfenidone, but the figure paid for the acquisition may be seen as validation for a Chinese biotech that has already commercialized its version of the drug for IPF.

BioPharmaceutical China

Cenova Touts Experience In Assessing Risk Of China Drug Development With Aslan Financing

Taking on the risk of a biotech investment in China takes experience, according to Shanghai-based Cenova Ventures, as a recent Series B finance round with Aslan Pharmaceuticals shows.

BioPharmaceutical China

Five NCEs Approved In China In 2011: A Closer Look At SFDA’s Progress Report

China’s SFDA recently released its third annual drug registration report. The agency approved 718 drugs and APIs in 2011, including five NCEs.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • GNI Group Ltd.
  • Senior Management
  • Ying Luo , PhD, Pres. & CEO
    Jun Wu, EVP, CSO
  • Contact Info
  • Shanghai Genomics Inc.
    Phone: (86) 21-50802786
    647 Song Tao Rd., Bldg. 1
    Shanghai, 201203
    China
UsernamePublicRestriction

Register